TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02430389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
Study: NCT03478592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reference technique
Description: Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
Study: NCT02138123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL-shell technique
Description: Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure
Description: In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
Study: NCT02979184

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive decongestive physiotherapy
Description: 2 weeks of intensive decongestive physiotherapy
Study: NCT02589756

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The nut group
Description: At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The nut group
Description: At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
Study: NCT02955719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT/Psychological Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Resources
Study: NCT03478592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitrification technique
Description: Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
Study: NCT02385591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support
Description: telephone-based physical activity advice and support delivered by a trained professional facilitator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Support
Description: Telephone-based physical activity advice and support delivered by SMS.
Study: NCT02556463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Subjects will receive durvalumab every 4 weeks
Study: NCT03215186

Intervention type: OTHER
Intervention: observational study
Study: NCT03563911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Intervention (BMBI)
Description: The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control/Nutrition Education
Description: The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
Study: NCT00403507

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Participation in a monitored exercise program
Description: No contact with control group during 20 weeks.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Participation in a monitored exercise program
Description: No contact with control group during 20 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized aerobic and strength training.
Description: Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
Study: NCT02775591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9701
Description: DA-9701 30mg Tablet
Study: NCT00403507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized aerobic and strength training.
Description: Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
Study: NCT02775591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-9701
Description: DA-9701 30mg Tablet
Study: NCT03337243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAM and HUMCWJ Injections
Description: SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
Study: NCT01796418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Study: NCT04117919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paper mulberry leaf
Description: Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (Encort-A) 0.1%15g/Tube
Description: only Topical steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Encort-A) 0.1%15g/Tube
Description: only Topical steroids
Study: NCT04037774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparision of different doses of dexmedetomidine used intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparision of different doses of dexmedetomidine used intrathecally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: addition of placebo with local anesthetic to create a control group
Study: NCT01053000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
Study: NCT02586246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870
Description: Self-injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870
Description: Self-injection
Study: NCT01547130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal (0.9%) saline
Description: A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely
Description: A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
Study: NCT03557879

Intervention type: GENETIC
Intervention: Exome sequencing
Description: DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
Study: NCT02549027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Oral MK-1064 tablets (10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Oral MK-1064 tablets (10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Oral MK-1064 tablets (10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Oral MK-1064 tablets (10 and 50 mg strengths)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: Oral MK-6096 tablets (5 mg strength)
Study: NCT02775591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-9701 placebo
Description: Placebo pill manufactured to mask DA-9701 30mg Tablet
Study: NCT00422630

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The DASH diet
Description: The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The low glycemic Index Diet
Description: The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced calorie American Diet
Description: The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
Study: NCT05347680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain Laryngeal Mask
Description: Ambu AuraGain Laryngeal Mask
Study: NCT03583268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
Study: NCT02540187

Intervention type: OTHER
Intervention: blood specimen

Intervention type: OTHER
Intervention: blood specimen
Study: NCT02749006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
Study: NCT03693677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Nal-IRI at 80 mg/m2 IV over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Nal-IRI at 80 mg/m2 IV over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU/LV
Description: 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
Study: NCT00663806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
Study: NCT03440151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral submental flap for tongue cancer defect
Description: Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary closure for tongue cancer defect
Description: Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
Study: NCT04568486

Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Empowerment Education Program
Description: The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
Study: NCT03702569

Intervention type: DIAGNOSTIC_TEST
Intervention: Left ventricular global longitudinal strain measure
Description: Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
Study: NCT01814397

Intervention type: DRUG
Intervention: Anastrozole
Description: 1 mg orally daily

Intervention type: DRUG
Intervention: exemestane
Description: 25 mg orally daily

Intervention type: DRUG
Intervention: letrozole
Description: 2.5 mg orally daily
Study: NCT02963168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oradoxel
Description: oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
Study: NCT01364454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eligible patients' paper-based reminder
Description: Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
Study: NCT01139203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine adefovir entecavir HBIG
Description: lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine adefovir entecavir HBIG
Description: lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine adefovir entecavir HBIG
Description: lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
Study: NCT00939289

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
Study: NCT04183504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief parenting intervention
Description: Coaching session on positive parenting practices and promoting child development
Study: NCT00879151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adolescents
Description: The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy for Bulimia Nervosa
Description: FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
Study: NCT02083341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lelo® Siri vibrator
Description: external vibration device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lelo® Siri vibrator
Description: external vibration device
Study: NCT02549027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: Oral MK-6096 tablets (5 mg strength)
Study: NCT02083341

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lelo® Siri vibrator with vibration component removed
Description: external vibration device - sham
Study: NCT02589756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The control group
Description: After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The control group
Description: After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.